CN116981691A - 抗原结合分子及其用途 - Google Patents

抗原结合分子及其用途 Download PDF

Info

Publication number
CN116981691A
CN116981691A CN202180091195.3A CN202180091195A CN116981691A CN 116981691 A CN116981691 A CN 116981691A CN 202180091195 A CN202180091195 A CN 202180091195A CN 116981691 A CN116981691 A CN 116981691A
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
ser
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180091195.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·J·布斯菲尔德
M·J·威尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skotebio GmbH
Original Assignee
Skotebio GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skotebio GmbH filed Critical Skotebio GmbH
Publication of CN116981691A publication Critical patent/CN116981691A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202180091195.3A 2020-11-23 2021-11-22 抗原结合分子及其用途 Pending CN116981691A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063117383P 2020-11-23 2020-11-23
US63/117,383 2020-11-23
PCT/US2021/060369 WO2022109403A1 (en) 2020-11-23 2021-11-22 Antigen-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
CN116981691A true CN116981691A (zh) 2023-10-31

Family

ID=81709767

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180091195.3A Pending CN116981691A (zh) 2020-11-23 2021-11-22 抗原结合分子及其用途

Country Status (8)

Country Link
US (1) US20230416356A1 (https=)
EP (1) EP4247848A4 (https=)
JP (1) JP2023550628A (https=)
KR (1) KR20230118864A (https=)
CN (1) CN116981691A (https=)
AU (1) AU2021383841A1 (https=)
CA (1) CA3199586A1 (https=)
WO (1) WO2022109403A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026017189A3 (zh) * 2024-07-19 2026-03-12 普米斯生物技术(珠海)有限公司 抗il-31抗体、其药物组合物及用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4602073A2 (en) * 2022-11-15 2025-08-20 Purdue Research Foundation Canine pd-l1 antibody, antigen binding fragments thereof, and methods of use thereof
GB202405576D0 (en) * 2024-04-19 2024-06-05 272Bio Ltd VHH antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970488A (zh) * 2007-12-07 2011-02-09 津莫吉尼蒂克斯公司 对il-31特异的人源化抗体分子
WO2013011407A1 (en) * 2011-07-21 2013-01-24 Ah Usa 42 Llc Interleukin-31 monoclonal antibody

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009138494A2 (en) * 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
JP2016522168A (ja) * 2013-04-05 2016-07-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−４抗体及び二重特異性抗体及びその使用
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
JP6800853B2 (ja) * 2014-12-11 2020-12-16 ピエール、ファーブル、メディカマン 抗ｃ１０ｏｒｆ５４抗体およびその使用
GB201621439D0 (en) * 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
US10093731B2 (en) * 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
MX2020006105A (es) * 2017-12-11 2020-11-09 Ubi Ip Holdings Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
CA3093539A1 (en) * 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
US11433139B2 (en) * 2018-03-16 2022-09-06 Zoetis Services Llc Peptide vaccines against interleukin-31
WO2019183449A1 (en) * 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for allergic disorders
US20190300610A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970488A (zh) * 2007-12-07 2011-02-09 津莫吉尼蒂克斯公司 对il-31特异的人源化抗体分子
WO2013011407A1 (en) * 2011-07-21 2013-01-24 Ah Usa 42 Llc Interleukin-31 monoclonal antibody
CN103890009A (zh) * 2011-07-21 2014-06-25 佐蒂斯有限责任公司 白细胞介素-31单克隆抗体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026017189A3 (zh) * 2024-07-19 2026-03-12 普米斯生物技术(珠海)有限公司 抗il-31抗体、其药物组合物及用途

Also Published As

Publication number Publication date
US20230416356A1 (en) 2023-12-28
KR20230118864A (ko) 2023-08-14
AU2021383841A1 (en) 2023-06-22
WO2022109403A1 (en) 2022-05-27
CA3199586A1 (en) 2022-05-27
JP2023550628A (ja) 2023-12-04
AU2021383841A9 (en) 2024-06-13
EP4247848A4 (en) 2025-10-01
EP4247848A1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
JP3978338B2 (ja) ヒトＩＬ−１βに対する抗体
KR102585324B1 (ko) 항-fam19a5 항체의 아데노-연관 바이러스(aav) 전달
CN117603354A (zh) 具有经修饰的ch2-ch3序列的犬抗体
CN114746440A (zh) 新型多肽复合物
CN116981691A (zh) 抗原结合分子及其用途
US20230110287A1 (en) Antigen-binding molecules and uses thereof
CN117003872A (zh) 含有突变轻链可变区骨架的单链抗体片段
US20250388683A1 (en) Anti-canine interleukine-31-receptor a (il-31ra) antibodies and the use thereof
CN116410319A (zh) 抗par2抗体及其用途
US20250011412A1 (en) Antigen-binding molecules and uses thereof
CN118176216A (zh) 抗icosl抗体融合蛋白及用途
EP4431528A1 (en) Isolated antigen binding protein and use thereof
CN118525034A (zh) 犬白介素-31受体αI的犬源化抗体
WO2024251255A1 (zh) 抗npr1抗体及其医药用途
CN121219319A (zh) 抗tigit抗体及其应用
WO2025185738A1 (zh) 靶向cxcr3的抗原结合蛋白及其应用
CN115572330A (zh) 一种特异性抗体及其制备方法和应用
WO2025051083A1 (zh) 抗bdca-2特异性抗体及其用途
HK40110110A (zh) 具有经修饰的ch2-ch3序列的犬抗体
CN118240091A (zh) 一种抗pd-l1和tigit双特异性抗体及其应用
HK40113191A (zh) 犬白介素-31受体αI的犬源化抗体
CN118240092A (zh) 一种抗pd-l1和tigit双特异性抗体融合蛋白及其应用
CN115215936A (zh) Csf1r抗原结合蛋白
HK40076302A (en) New polypeptide complex

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination